Clinical Trials Browser

Withdrawn × OTHER × Trastuzumab × Clear all

NCT04419181 2025-10-14

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Phase 2 Withdrawn

HER2-positive Breast Cancer

NCT05356897 2024-09-19

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT04512261 2022-07-01

TOPAZ

Phase 1/2 Withdrawn

Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases

NCT03846583 2020-10-23

Tucatinib + Abemaciclib + Herceptin for HER2+ MBC

Phase 1 Withdrawn

Breast Neoplasms

NCT02735798 2017-05-04

64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets

Phase EARLY_PHASE1 Withdrawn

Brain Neoplasms

NCT00397501 2017-04-21

BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain

Phase 1/2 Withdrawn

Brain Neoplasms, Breast Neoplasms, Central Nervous System Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT01479179 2016-10-26

Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

Phase 1/2 Withdrawn

Breast Neoplasms

NCT02102438 2016-08-31

Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer

Phase NA Withdrawn

Breast Neoplasms

NCT00053339 2016-07-12

Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer

Phase 3 Withdrawn

Breast Neoplasms

NCT01985893 2016-01-14

THOR

Phase 2 Withdrawn

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01557764 2013-07-04

Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT00434031 2012-07-30

CETRA

Phase 2 Withdrawn

Breast Neoplasms

NCT00054470 2012-06-29

Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms, Breast Neoplasms, Male

NCT00057993 2012-06-11

Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms